Best GLP-1 Agonists Newsletters in 2026
NewsletterFIT tracks 3 newsletters that cover GLP-1 agonists as a primary topic, all with posts in the last 90 days. By publicly shown subscriber count, the largest are GLP-1 Digest (2K).
Updated Nov 12, 2026 · sorted by publicly shown subscribers · methodology
- 1GLP-1 Digest 2K subscribers
SubstackMonthly or less · last post 34 days ago
From recent posts: GLP-1 Digest publishes weekly interviews and analysis covering the GLP-1 market, companion apps, genetic testing, and regulatory issues for investors, healthcare professionals, and entrepreneurs. The publication mixes…
Likely audience: Healthcare investors
- 2
SubstackSeveral times a week · last post 2 days ago
From recent posts: This article analyzes Eli Lilly's phase 3 trial results for retatrutide, a triple agonist drug, comparing its efficacy and side effects against semaglutide in adults with type 2 diabetes. The author details the trial de…
Likely audience: Endocrinologists
- 3
SubstackWeekly · last post 6 days ago
From recent posts: This article reviews a supplier's peptide kits, detailing significant price reductions for specific compounds like retatrutide and semaglutide between April and October. The author also examines the availability of raw…
Likely audience: Healthcare professionals
Latest posts from these newsletters
- GLP-1s Aren’t…drjessemorse
- Stem Cells…drjessemorse
- The First…drjessemorse
- A Longevity…drjessemorse
- The Next…drjessemorse
- Who Actually…peptidesweekly
- THE PEPTIDE…peptidesweekly
- Doctors Want…drjessemorse